


## Data Sheet

<b>Product Name:</b>	Loxapine
<b>Cat. No.:</b>	CS-1105
<b>CAS No.:</b>	1977-10-2
<b>Molecular Formula:</b>	C <sub>18</sub> H <sub>18</sub> ClN <sub>3</sub> O
<b>Molecular Weight:</b>	327.81
<b>Target:</b>	5-HT Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Solubility:</b>	DMSO : ≥ 33.33 mg/mL (101.67 mM)



### BIOLOGICAL ACTIVITY:

Loxapine Succinate is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti-psychotic agent. IC<sub>50</sub> value: Target: D2DR/D4DR; 5-HT receptor in vitro: In the presence of Loxapine, [3H]ketanserin binds to 5-HT<sub>2</sub> receptor in Frontal cortex of brain in human and bovine with *k<sub>i</sub>* value of 6.2 nM and 6.6 nM, respectively. Loxapine has the rank order of potency for the various receptors appears to be as follows: 5-HT<sub>2</sub> ≥ D<sub>4</sub> > > D<sub>1</sub> > D<sub>2</sub> in comparing competition experiments involving the human membranes [1]. Loxapine 0.2 μM, 2 μM and 20 μM reduces IL-1β secretion by LPS-activated mixed glia cultures after 1 and 3 days of exposure. Loxapine in concentrations of 0.2 μM, 2 μM and 20 μM reduces IL-2 secretion in mixed glia cultures after 1 and 3 days of exposure, and additionally Loxapine decreases IL-1β and IL-2 secretion in LPS-induced microglia cultures in concentrations of 2 μM, 10 μM and 20 μM [2]. in vivo: Loxapine (5 mg/kg) induces a very significant reduction (more than 50%) of serotonin (5-HT<sub>2</sub>) receptor density after 4 weeks or 10 weeks of daily injection in the rat. Loxapine (5 mg/kg) does not change dopamine receptor density but greatly reduces serotonin receptor density by 47% in the brain of rats [3].

### References:

- [1]. Singh AN, et al. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D<sub>1</sub>, D<sub>2</sub>, D<sub>4</sub> and serotonin 5-HT<sub>2</sub> receptor subtypes. *J Psychiatry Neurosci.* 1996 Jan;21(1):29-35.
- [2]. Labuzek K, et al. Chlorpromazine and loxapine reduce interleukin-1β and interleukin-2 release by rat mixed glial and microglial cell cultures. *Eur Neuropsychopharmacol.* 2005 Jan;15(1):23-30.
- [3]. Lee T, et al. Loxapine and clozapine decrease serotonin (5-HT<sub>2</sub>) but do not elevate dopamine (D<sub>2</sub>) receptor numbers in the rat brain. *Psychiatry Res.* 1984 Aug;12(4):277-85.
- [4]. Kalkman HO, et al. Clozapine inhibits catalepsy induced by olanzapine and loxapine, but prolongs catalepsy induced by SCH 23390 in rats. *Naunyn-Schmiedeberg's Arch Pharmacol.* 1997 Mar;355(3):361-4.

### CAIndexNames:

Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-

### SMILES:

CN1CCN(C2=NC3=CC=CC=C3OC4=CC=C(Cl)C=C24)CC1

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: [sales@ChemScene.com](mailto:sales@ChemScene.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA